This week

Weekly LLM-curated digest of pipeline moves, readouts, guideline changes, and the prompts that generate them.

Weekly brief Add data

What's new this week

ISO week starting 2026-04-20 · 5514 changes from ingest

New approvals (62)

minocycline hydrochloride extended-release — Rosacea (FDA)
dexamethasone — Rosacea (FDA)
benzoyl peroxide — Rosacea (FDA)
dexamethasone sodium phosphate — Rosacea (FDA)
prednisolone sodium phosphate — Rosacea (FDA)
tobramycin — Rosacea (FDA)
doxycycline — Rosacea (FDA)
prednisolone acetate — Rosacea (FDA)
brimonidine — Rosacea (FDA)
minocycline — Rosacea (FDA)
fluocinonide — Rosacea (FDA)
repository corticotropin — Psoriasis (FDA)
azelaic acid — Rosacea (FDA)
apremilast — Psoriasis (FDA)
deucravacitinib — Psoriasis (FDA)
ivermectin — Rosacea (FDA)
metronidazole — Rosacea (FDA)
brimonidine tartrate — Rosacea (FDA)
oxymetazoline hydrochloride — Rosacea (FDA)
nickel sulfate — Rosacea (FDA)
potassium bromide — Rosacea (FDA)
sodium bromide — Rosacea (FDA)
zinc sulfate — Rosacea (FDA)
loteprednol etabonate — Rosacea (FDA)
sodium sulfacetamide — Rosacea (FDA)
sulfur — Rosacea (FDA)
clobetasol propionate — Rosacea (FDA)
hydrocortisone butyrate — Seborrheic dermatitis (FDA)
potassium bromide — Seborrheic dermatitis (FDA)
nickel sulfate — Seborrheic dermatitis (FDA)
zinc bromide — Seborrheic dermatitis (FDA)
dexamethasone — Seborrheic dermatitis (FDA)
gentamicin sulfate — Seborrheic dermatitis (FDA)
tralokinumab — Atopic dermatitis (FDA)
ammonia — Atopic dermatitis (FDA)
nemolizumab — Atopic dermatitis (FDA)
roflumilast — Atopic dermatitis (FDA)
repository corticotropin — Atopic dermatitis (FDA)
ciclopirox — Seborrheic dermatitis (FDA)
ketoconazole — Seborrheic dermatitis (FDA)
roflumilast — Seborrheic dermatitis (FDA)
sodium sulfacetamide — Seborrheic dermatitis (FDA)
sulfur — Seborrheic dermatitis (FDA)
selenium sulfide — Seborrheic dermatitis (FDA)
nemolizumab — Prurigo nodularis (FDA)
cetirizine — Chronic urticaria (FDA)
desloratadine — Chronic urticaria (FDA)
remibrutinib — Chronic urticaria (FDA)
cetirizine hydrochloride — Chronic urticaria (FDA)
levocetirizine dihydrochloride — Chronic urticaria (FDA)
hydrocortisone — Acne vulgaris (FDA)
prednisolone sodium phosphate — Acne vulgaris (FDA)
sarecycline — Acne vulgaris (FDA)
aloe polysaccharides — Acne vulgaris (FDA)
minocycline — Acne vulgaris (FDA)
hydrocortisone acetate — Acne vulgaris (FDA)
iodoquinol — Acne vulgaris (FDA)
azelaic acid — Acne vulgaris (FDA)
nickel sulfate — Acne vulgaris (FDA)
potassium bromide — Acne vulgaris (FDA)
sodium bromide — Acne vulgaris (FDA)
zinc sulfate — Acne vulgaris (FDA)

New ingredients (31)

metronidazole · openfda
minocycline hydrochloride extended-release · openfda
brimonidine · openfda
oxymetazoline hydrochloride · openfda
ketoconazole · openfda
selenium sulfide · openfda
ciclopirox · openfda
cetirizine hydrochloride · openfda
desloratadine · openfda
levocetirizine dihydrochloride · openfda
cetirizine · openfda
remibrutinib · openfda
brimonidine tartrate · openfda
doxycycline · openfda
ivermectin · openfda
fluocinonide · openfda
repository corticotropin · openfda
daspone · openfda
zinc sulfate · openfda
sodium bromide · openfda
doxyclycline hyclate · openfda
azelaic acid · openfda
minocycline · openfda
sarecycline hydrochloride · openfda
clindamycin phosphate/benzoyl peroxide/adapalene · openfda
drospirenone/ethinyl estradiol/levomefolate calcium · openfda
nemolizumab · openfda
ammonia · openfda
tralokinumab · openfda
deucravacitinib · openfda
apremilast · openfda

New trials (5417)

NCT07106957 (NA) — Efficacy and Safety Evaluation of CICAPLAST BAUME B5+ on Rosacea Accompanied by
NCT03340961 (PHASE2) — A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-2
NCT02393937 (PHASE3) — A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments o
NCT03954444 (PHASE3) — A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
NCT04106726 (PHASE3) — Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe F
NCT01666509 (NA) — Efficacy and Tolerability of Topical Rossoseq™ Compared to Vehicle in Rosacea Su
NCT05150587 (PHASE2) — Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-
NCT00668655 — An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%
NCT03048058 (PHASE4) — Internet Surveys and Their Impact on Adherence for Rosacea
NCT02800148 (PHASE3) — Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions
NCT02749786 (NA) — Genetic Basis of Rosacea Study (Control)
NCT07410533 (NA) — Analysis of Factors Associated With the Efficacy of 595-nm Pulsed Dye Laser Trea
NCT05360251 (NA) — Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength B
NCT03478436 (PHASE1) — Pharmacokinetics of Doxycycline in Skin of Healthy Volunteers
NCT01257750 (PHASE1) — Treatment of Corneal Neovascularization With Topical Pazopanib
NCT04898582 (NA) — Clinical Benefit of M89PB in Subjects With Rosacea Associated With Erythema and
NCT01355458 (PHASE3) — Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Fac
NCT01763437 (EARLY_PHASE1) — Intralesional Tetracycline Injection in the Treatment of Chalazia
NCT01828177 (PHASE2) — An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea
NCT01789775 (PHASE3) — Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Fac
…and 5397 more

MOA enrichment (4)

azelaic acid · openfda
ketoconazole · openfda
ciclopirox · openfda
metronidazole · openfda

2026-W16

source: gemini

This weekly brief summarizes key regulatory, clinical, and guideline developments in the fields of psoriasis and atopic dermatitis (AD) for the period of April 1, 2026, to April 17, 2026.

Approvals

Anzupgo (delgocitinib) cream — FDA sNDA Acceptance · April 15, 2026 Source: leo-pharma.com/media-center/news/2026-acceptance-of-anzupgo-snda Why it matters: If approved, this topical pan-JAK inhibitor would be the first indicated treatment specifically for pediatric patients (ages 12–17) with moderate-to-severe chronic hand eczema (CHE).

Icotyde (icotrokinra) — Commercial Launch/Update · April 7, 2026 Source: fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 Why it matters: Following its mid-March approval, new 1-year data confirmed its position as the first targeted oral peptide for IL-23 receptor antagonism, offering biologic-like efficacy in a daily pill for plaque psoriasis.

Trial readouts

Zasocitinib — Phase 3 LATITUDE results (Full Data) · April 7, 2026 Source: clinicaltrials.gov/study/NCT06671483 / hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Demonstrated superiority over placebo and apremilast in moderate-to-severe psoriasis, with nearly 30% of patients achieving PASI 100 at week 16, reinforcing the strength of the next-gen TYK2 inhibitor pipeline.

Rademikibart — Phase 3 RADIANT-AD 52-week data · April 7, 2026 Source: hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Long-term data showed sustained near-maximal skin clearance and pruritus control through one year, establishing it as a highly durable IL-4Rα antagonist competitor.

Guideline / safety updates

AAD 2026 Guidelines: Management of Atopic Dermatitis in Pediatric Patients — Publication · April 7, 2026 Source: jaad.org/article/S0190-9622(26)00113-X/fulltext Why it matters: The first pediatric-specific AD guidelines from the AAD, granting "Strong" evidence-based recommendations for aryl hydrocarbon receptor (AhR) agonists like tapinarof in children as young as 2 years old.

International Eczema Council (IEC) Consensus Statement — JAMA Dermatology · April 15, 2026 Source: jamanetwork.com/journals/jamadermatology/fullarticle/2816625 Why it matters: Standardizes the definitions for "Low Disease Activity" and "Remission" in AD, providing essential benchmarks for clinical trial design and "treat-to-target" strategies in routine practice.